Literature DB >> 15048901

Paroxetine retards disease onset and progression in Huntingtin mutant mice.

Wenzhen Duan1, Zhihong Guo, Haiyang Jiang, Bruce Ladenheim, Xiangru Xu, Jean Lud Cadet, Mark P Mattson.   

Abstract

We report that administration of paroxetine, a widely prescribed antidepressant drug that acts by inhibiting reuptake of the neurotransmitter serotonin, suppresses the neurodegenerative process and increases the survival of huntingtin mutant mice, an animal model of Huntington's disease (HD). Paroxetine attenuated motor dysfunction and body weight loss and improved glucose metabolism in the HD mice. Paroxetine was beneficial when treatment was initiated before or after the onset of motor dysfunction, suggesting a potential for such antidepressant drugs in the treatment of presymptomatic and symptomatic HD patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15048901     DOI: 10.1002/ana.20075

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  28 in total

1.  Therapeutics in Huntington's Disease.

Authors:  Annie Killoran; Kevin M Biglan
Journal:  Curr Treat Options Neurol       Date:  2012-02-08       Impact factor: 3.598

2.  Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease.

Authors:  Wenzhen Duan; Qi Peng; Naoki Masuda; Eric Ford; Erik Tryggestad; Bruce Ladenheim; Ming Zhao; Jean Lud Cadet; John Wong; Christopher A Ross
Journal:  Neurobiol Dis       Date:  2008-03-10       Impact factor: 5.996

3.  Antidepressants tested for everything from hot flashes to stroke.

Authors:  Michelle Pflumm
Journal:  Nat Med       Date:  2011-03       Impact factor: 53.440

4.  Spatiotemporal mapping of brain atrophy in mouse models of Huntington's disease using longitudinal in vivo magnetic resonance imaging.

Authors:  Manisha Aggarwal; Wenzhen Duan; Zhipeng Hou; Neal Rakesh; Qi Peng; Christopher A Ross; Michael I Miller; Susumu Mori; Jiangyang Zhang
Journal:  Neuroimage       Date:  2012-02-09       Impact factor: 6.556

5.  Patterns of serotonergic antidepressant usage in prodromal Huntington disease.

Authors:  Kelly C Rowe; Jane S Paulsen; Douglas R Langbehn; Chiachi Wang; James Mills; Leigh J Beglinger; Megan M Smith; Eric A Epping; Jess G Fiedorowicz; Kevin Duff; Adam Ruggle; David J Moser
Journal:  Psychiatry Res       Date:  2012-03-05       Impact factor: 3.222

6.  A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.

Authors:  Danielle A Simmons; Nadia P Belichenko; Tao Yang; Christina Condon; Marie Monbureau; Mehrdad Shamloo; Deqiang Jing; Stephen M Massa; Frank M Longo
Journal:  J Neurosci       Date:  2013-11-27       Impact factor: 6.167

Review 7.  Glutamate and neurotrophic factors in neuronal plasticity and disease.

Authors:  Mark P Mattson
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

Review 8.  Activity-dependent, stress-responsive BDNF signaling and the quest for optimal brain health and resilience throughout the lifespan.

Authors:  S M Rothman; M P Mattson
Journal:  Neuroscience       Date:  2012-10-16       Impact factor: 3.590

Review 9.  Mitochondria in neuroplasticity and neurological disorders.

Authors:  Mark P Mattson; Marc Gleichmann; Aiwu Cheng
Journal:  Neuron       Date:  2008-12-10       Impact factor: 17.173

10.  The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model.

Authors:  Qi Peng; Naoki Masuda; Mali Jiang; Qing Li; Ming Zhao; Christopher A Ross; Wenzhen Duan
Journal:  Exp Neurol       Date:  2007-11-09       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.